-
1
-
-
42449114035
-
Multiple myeloma
-
Kyle RA, Rajkumar SV. Multiple myeloma. Blood 2008;111: 2962-72.
-
(2008)
Blood
, vol.111
, pp. 2962-2972
-
-
Kyle, R.A.1
Rajkumar, S.V.2
-
2
-
-
63849093676
-
Myeloma bone disease: Recent advances in biology, diagnosis and treatment
-
Sezer O. Myeloma bone disease: recent advances in biology, diagnosis and treatment. Oncologist 2009;14:276-83.
-
(2009)
Oncologist
, vol.14
, pp. 276-283
-
-
Sezer, O.1
-
3
-
-
51649090583
-
Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma
-
Jakob C, Sterz J, Liebisch P, et al. Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma. Leukemia 2008;22:1767-72.
-
(2008)
Leukemia
, vol.22
, pp. 1767-1772
-
-
Jakob, C.1
Sterz, J.2
Liebisch, P.3
-
4
-
-
34548133601
-
Bortezomib inhibits human osteoclastogenesis
-
von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007;21: 2025-34.
-
(2007)
Leukemia
, vol.21
, pp. 2025-2034
-
-
von Metzler, I.1
Krebbel, H.2
Hecht, M.3
-
5
-
-
34548128339
-
The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
-
Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007;21:1875-84.
-
(2007)
Leukemia
, vol.21
, pp. 1875-1884
-
-
Terpos, E.1
Dimopoulos, M.A.2
Sezer, O.3
-
6
-
-
34447335316
-
Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK
-
Hecht M, Heider U, Kaiser M, von Metzler I, Sterz J, Sezer O. Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br J Haematol 2007;138:446-58.
-
(2007)
Br J Haematol
, vol.138
, pp. 446-458
-
-
Hecht, M.1
Heider, U.2
Kaiser, M.3
von Metzler, I.4
Sterz, J.5
Sezer, O.6
-
7
-
-
34447266200
-
An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma
-
Cocks K, Cohen D, Wisloff F, et al. An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 2007;43:1670-8.
-
(2007)
Eur J Cancer
, vol.43
, pp. 1670-1678
-
-
Cocks, K.1
Cohen, D.2
Wisloff, F.3
-
8
-
-
54049135250
-
Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial
-
Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008;112:3107-14.
-
(2008)
Blood
, vol.112
, pp. 3107-3114
-
-
Palumbo, A.1
Bringhen, S.2
Liberati, A.M.3
-
9
-
-
50449086728
-
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma
-
San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008;359:906-17.
-
(2008)
N Engl J Med
, vol.359
, pp. 906-917
-
-
San Miguel, J.F.1
Schlag, R.2
Khuageva, N.K.3
-
10
-
-
0346336804
-
Treatment of multiple myeloma
-
Barlogie B, Shaughnessy J, Tricot G, Jacobson J, Zangari M, Anaissie E, Walker R, Crowley J. Treatment of multiple myeloma. Blood 2004;103:20-32.
-
(2004)
Blood
, vol.103
, pp. 20-32
-
-
Barlogie, B.1
Shaughnessy, J.2
Tricot, G.3
Jacobson, J.4
Zangari, M.5
Anaissie, E.6
Walker, R.7
Crowley, J.8
-
12
-
-
33747679267
-
Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma
-
Duus J, Bahar HI, Venkataraman G, Ozpuyan F, Izban KF, Al-Masri H, Maududi T, Toor A, Alkan S. Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk Lymphoma 2006;47:1369-78.
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 1369-1378
-
-
Duus, J.1
Bahar, H.I.2
Venkataraman, G.3
Ozpuyan, F.4
Izban, K.F.5
Al-Masri, H.6
Maududi, T.7
Toor, A.8
Alkan, S.9
-
13
-
-
33644554220
-
The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma
-
Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006;91:248-51.
-
(2006)
Haematologica
, vol.91
, pp. 248-251
-
-
Kaiser, M.1
Zavrski, I.2
Sterz, J.3
Jakob, C.4
Fleissner, C.5
Kloetzel, P.M.6
Sezer, O.7
Heider, U.8
-
14
-
-
31544436323
-
Antimyeloma activity of heat shock protein-90 inhibition
-
Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092- 100.
-
(2006)
Blood
, vol.107
, pp. 1092-1100
-
-
Mitsiades, C.S.1
Mitsiades, N.S.2
McMullan, C.J.3
-
15
-
-
49449105426
-
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
-
Stuhmer T, Zollinger A, Siegmund D, et al. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma. Leukemia 2008;22:1604-12.
-
(2008)
Leukemia
, vol.22
, pp. 1604-1612
-
-
Stuhmer, T.1
Zollinger, A.2
Siegmund, D.3
-
16
-
-
28644440158
-
Histone deacetylase inhibitors: Discovery and development as anticancer agents
-
Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 2005;14:1497-511.
-
(2005)
Expert Opin Investig Drugs
, vol.14
, pp. 1497-1511
-
-
Marks, P.A.1
Dokmanovic, M.2
-
17
-
-
22844432021
-
Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors
-
Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem 2005;280:26729-34.
-
(2005)
J Biol Chem
, vol.280
, pp. 26729-26734
-
-
Bali, P.1
Pranpat, M.2
Bradner, J.3
-
18
-
-
33745258655
-
The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance
-
Maiso P, Carvajal-Vergara X, Ocio EM, Lopez-Perez R, Mateo G, Gutierrez N, Atadja P, Pandiella A, San Miguel JF. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance. Cancer Res 2006;66:5781-9.
-
(2006)
Cancer Res
, vol.66
, pp. 5781-5789
-
-
Maiso, P.1
Carvajal-Vergara, X.2
Ocio, E.M.3
Lopez-Perez, R.4
Mateo, G.5
Gutierrez, N.6
Atadja, P.7
Pandiella, A.8
San Miguel, J.F.9
-
19
-
-
0021118703
-
Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
-
Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
-
(1984)
Adv Enzyme Regul
, vol.22
, pp. 27-55
-
-
Chou, T.C.1
Talalay, P.2
-
20
-
-
0043164960
-
Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion
-
Zavrski I, Naujokat C, Niemoller K, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003;129:383-91.
-
(2003)
J Cancer Res Clin Oncol
, vol.129
, pp. 383-391
-
-
Zavrski, I.1
Naujokat, C.2
Niemoller, K.3
-
21
-
-
65349193958
-
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: An effective and well-tolerated frontline regimen
-
Berenson JR, Yellin O, Woytowitz D, et al. Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen. Eur J Haematol 2009; 82:433-9.
-
(2009)
Eur J Haematol
, vol.82
, pp. 433-439
-
-
Berenson, J.R.1
Yellin, O.2
Woytowitz, D.3
-
22
-
-
33644843725
-
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: Randomised controlled trial
-
Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006;367:825-31.
-
(2006)
Lancet
, vol.367
, pp. 825-831
-
-
Palumbo, A.1
Bringhen, S.2
Caravita, T.3
-
23
-
-
33947386313
-
Synergism between etoposide and 17-AAG in leukemia cells: Critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51
-
Yao Q, Weigel B, Kersey J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 2007;13:1591-600.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 1591-1600
-
-
Yao, Q.1
Weigel, B.2
Kersey, J.3
-
24
-
-
0038404927
-
Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol
-
Solit DB, Basso AD, Olshen AB, Scher HI, Rosen N. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer Res 2003;63:2139-44.
-
(2003)
Cancer Res
, vol.63
, pp. 2139-2144
-
-
Solit, D.B.1
Basso, A.D.2
Olshen, A.B.3
Scher, H.I.4
Rosen, N.5
-
25
-
-
22044437522
-
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
-
Mesa RA, Loegering D, Powell HL, et al. Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine. Blood 2005;106:318-27.
-
(2005)
Blood
, vol.106
, pp. 318-327
-
-
Mesa, R.A.1
Loegering, D.2
Powell, H.L.3
-
26
-
-
21744462772
-
Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-Inhibition of P-glycoprotein function by 17-AAG
-
Radujkovic A, Schad M, Topaly J, et al. Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL-Inhibition of P-glycoprotein function by 17-AAG. Leukemia 2005;19:1198-206.
-
(2005)
Leukemia
, vol.19
, pp. 1198-1206
-
-
Radujkovic, A.1
Schad, M.2
Topaly, J.3
-
27
-
-
36148931442
-
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia
-
Johnson AJ, Wagner AJ, Cheney CM, Smith LL, Lucas DM, Guster SK, Grever MR, Lin TS, Byrd JC. Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J Haematol 2007;139:837-44.
-
(2007)
Br J Haematol
, vol.139
, pp. 837-844
-
-
Johnson, A.J.1
Wagner, A.J.2
Cheney, C.M.3
Smith, L.L.4
Lucas, D.M.5
Guster, S.K.6
Grever, M.R.7
Lin, T.S.8
Byrd, J.C.9
-
28
-
-
20844444898
-
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
-
George P, Bali P, Annavarapu S, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 2005;105:1768-76.
-
(2005)
Blood
, vol.105
, pp. 1768-1776
-
-
George, P.1
Bali, P.2
Annavarapu, S.3
-
29
-
-
52649133274
-
HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells
-
Rao R, Fiskus W, Yang Y, et al. HDAC6 inhibition enhances 17-AAG-mediated abrogation of hsp90 chaperone function in human leukemia cells. Blood 2008;112:1886-93.
-
(2008)
Blood
, vol.112
, pp. 1886-1893
-
-
Rao, R.1
Fiskus, W.2
Yang, Y.3
-
30
-
-
0034890377
-
Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner
-
Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001;7:2228-36.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2228-2236
-
-
Munster, P.N.1
Basso, A.2
Solit, D.3
Norton, L.4
Rosen, N.5
-
31
-
-
0034886833
-
Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: Sequence and tumor biology matters
-
Sausville EA. Combining cytotoxics and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor biology matters. Clin Cancer Res 2001;7:2155-8.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 2155-2158
-
-
Sausville, E.A.1
-
32
-
-
33751203833
-
Heat shock proteins 27 and 70: Anti-apoptotic proteins with tumorigenic properties
-
Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, Kroemer G. Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 2006;5:2592-601.
-
(2006)
Cell Cycle
, vol.5
, pp. 2592-2601
-
-
Garrido, C.1
Brunet, M.2
Didelot, C.3
Zermati, Y.4
Schmitt, E.5
Kroemer, G.6
|